BSH/ISH 2016 | Drug combinations in CLL: ibrutinib, idelalisib and more
Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY discusses the mechanism of action of ibrutinib and idelalisib and further drug combinations under investigation in CLL. Both drugs impact the growth and survival of CLL cells but in a parallel way according to Dr Zelenetz. He further discusses various studies looking at combinations, such as idelalisib with BTK inhibitor ONO-4059, and PI3K delta inhibitor ME-401 with a novel BTK inhibitor.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.
Get great new content delivered to your inboxSign up